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Abstract: Paclitaxel is a front-line agent for ovarian cancer chemotherapy, along with the 
platinum agents. Derived from the Pacific yew tree, Taxus brevifolia, paclitaxel has covered 
significant ground from the initial discovery of its antineoplastic properties to clinical applications 
in many forms of human cancers, including ovarian cancer. Although much has been published 
about the unique mechanism of action of this agent, several issues remain to be resolved. Finding 
the appropriate dosage schedule for paclitaxel in chemo-naïve and recurrent ovarian cancer, 
defining the role of paclitaxel in maintenance chemotherapy, and elucidating the mechanisms of 
taxane resistance are areas of intense research. Newer forms of taxanes are being manufactured 
to avoid troublesome adverse effects and to improve clinical efficacy. These issues are reviewed 
in detail in this paper with an emphasis on clinically relevant evidence-based information.
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Epithelial ovarian cancer
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in 
the US. An estimated 21,650 new cases and 15,520 deaths were attributed to ovarian 
cancer, representing 6% of all cancer deaths recorded in the US in 2008.1 One woman 
in 70 will develop ovarian cancer, and one woman in 100 will die of the disease.1,2 
The incidence of ovarian cancer increases with age. There is a particularly steep rise 
in incidence starting from the fifth decade of life, peaking in the eighth decade.
Serous carcinoma is the most common histologic type of ovarian cancer in all racial 
and ethnic groups, followed by mucinous, endometrioid, and clear cell carcinoma.2 
Transitional, mixed, and undifferentiated histology are the uncommon types of ovarian 
cancer. Symptoms of the disease are nonspecific and there are no effective screening 
tests available for the general population. As a result, diagnosis often occurs when the 
disease is already at an advanced stage, and hence the prognosis is poor. Abdominal 
pain/discomfort, abdominal distension, or gastrointestinal symptoms (eg, nausea, 
vomiting, and dyspepsia) are the most frequent presenting complaints but, occasion-
ally, urinary symptoms or vaginal bleeding predominates. Physical examination usu-
ally detects ascites and pelvic mass. Imaging in the form of ultrasound and computed 
tomography scans confirm the findings in the abdomen and pelvis.
Risk factors for ovarian cancer include family history of ovarian/breast cancer, 
nulliparity, early menarche, late menopause, white race, and higher socioeconomic 
status.3 Protective factors include multiparity, use of the oral contraceptive pill, and tubal 
ligation.3,4 Although ovarian cancer still carries an extremely high case   fatality ratio, 
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to 45% during 1996–2002.1 Age is associated with signifi-
cant prognostic implications in ovarian cancer. The five-year 
survival rates by age groups are 78.8%, 58.8%, and 35.3% 
for very young (,30 years), young (30–60) and older (.60) 
individuals, respectively.5
Historic overview
The National Cancer Institute (NCI) initiated a screening 
program to identify the biologic antitumor activity of thou-
sands of naturally occurring plants in the 1960s, during which 
time a crude extract from the bark of the Pacific yew, Taxus 
brevifolia, showed activity against many tumor types.6 This 
is a slow-growing evergreen plant found in the old-growth 
forests of the Northwest Pacific. In 1971, investigators 
were able to isolate the active ingredient, paclitaxel, from 
the crude bark extract.6 In 1979, Horwitz et al noted that 
the drug prevented cell division by promoting the assembly 
of microtubules without inhibiting their disassembly.7 In the 
initial phases, development was slow because paclitaxel 
did not appear to be more effective than other agents under 
development, and the procurement of this potentially scarce 
natural product in adequate quantities was deemed to be 
labor- and cost-intensive. However, paclitaxel displayed 
impressive activity in human tumor xenografts in nude mice 
and, by the mid-1980s, the NCI had initiated the clinical 
Phase I trials.8
Structure
The chemical name of paclitaxel is 5β, 20-epoxy-1,2α,4, 
7β,10β,13α-hexahydroxytax-11-en-9-one4, 10-diacetate 
2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenyli-
soserine. The chemical formula of paclitaxel is C47H51O14, 
with a molecular weight of 853.9. It is highly lipophilic, 
insoluble in water, and melts at 217°C. The structure of pacli-
taxel is in the form of a complex ring system that is linked 
to a four-member oxetan ring at positions C4 and C5 and to 
an ester side chain at C13. Some studies suggested that this 
side chain is responsible for the unique effect of paclitaxel 
on microtubules.9,10 In contrast, other studies showed that 
the side chain is not an absolute requirement for the biologic 
activity of paclitaxel, but lack of this may confer a structure 
that is not as active as paclitaxel.10,11
Mechanism of action
Microtubules play a key role in the initiation of DNA syn-
thesis, mitosis, meiosis, motility, maintenance of cellular 
shape, and intracellular trafficking of macromolecules and 
organelles. Paclitaxel binds selectively and reversibly to 
the B subunit of tubulin, promoting tubulin   polymerization 
and formation of stable microtubules even in the absence 
of the energy source, guanosine triphosphate. This effect 
leads to disruption of the equilibrium between the tubulin 
dimer-polymer in favor of polymer assembly.12,13 Paclitaxel-
induced microtubules have unusual stability and resist 
depolymerization by calcium, cold temperature, and dilu-
tion. Cells exposed to the drug exhibit an accumulation of 
arrays of disorganized microtubules which cause profound 
cell cycle arrest at the G2/M phase and eventually result 
in cell death through an apoptotic pathway.12,13 Paclitaxel 
induces two distinct microtubular structures, ie, bundles 
and esters, which can be visualized by antitubulin anti-
body staining. Cells with esters produced by paclitaxel 
exposure are in mitosis and cells with paclitaxel-induced 
bundles are in the G0/G1, S, and G2 phases.9 At high con-
centration, paclitaxel increases polymer mass and induces 
microtubule bundle formation, while at low concentration 
the principal effect is suppression of microtubule dynam-
ics without altering the polymer mass.14,15 At a molecular 
level, paclitaxel-induced apoptosis and drug resistance is 
thought to be mediated through alteration in function of 
p53, p21, Bcl-2, and Bcl-xL.16,17 Specifically, apoptosis 
mediated by caspase 3 and caspase 8, hyperphosphoryla-
tion of Bcl-2, and increased expression of Bax have been 
shown to be partly responsible for   paclitaxel-associated 
cytotoxicity.18,19
Pharmacokinetics
Paclitaxel is a large complex structure, insoluble in water, 
and .95% bound to protein. Therefore, paclitaxel uptake in 
the brain and testes is minimal, as demonstrated by radio-
labeled drug studies.20 The bioavailability of paclitaxel is 
poor after oral administration due to enterocyte expression of 
P-glycoprotein (Pgp) and first-pass metabolism in the liver. 
Parental administration is therefore required. Early studies 
with prolonged infusions of paclitaxel were suggestive of 
linear pharmacokinetics. However, later studies showed 
that paclitaxel followed nonlinear pharmacokinetics due to 
saturable distribution, metabolism, and elimination. This is 
especially evident with shorter durations of infusion and/or 
high dose levels.21 At higher doses and administration rates, 
the plasma concentration of paclitaxel begins to exceed the 
metabolic capacity of the elimination pathways, thereby 
disproportionately increasing the area under the plasma-time 
curve.22,23 The clinical implication of nonlinearity is that dose 
escalation may result in a disproportionate increase in toxicity, 
whereas dose reduction may result in a   disproportionate International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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decrease in efficacy. The pharmaceutical vehicle used to 
dissolve paclitaxel, ie, Cremopher® EL, may affect the dis-
position of the drug and contribute to the reduction in plasma 
clearance observed at higher doses of paclitaxel.22 Pharma-
codynamic analyses have strongly indicated that there is a 
relationship between percentage decrease in white blood cell 
count or absolute neutrophil count and the time for which 
plasma paclitaxel concentration is above the threshold level 
of 0.1 µmol/L.22,23
Metabolism
The major pathway of elimination for paclitaxel is hepatic 
metabolism followed by biliary excretion. Renal clear-
ance is minimal, with less than 15% of the drug excreted 
in urine. Paclitaxel is metabolized by CYP3A4 and 
CYP2C8; 6α-hydroxy-paclitaxel is the major metabolite 
of paclitaxel that is formed by hydroxylation of C6 in the 
taxane ring by CYP2C8. This metabolite is approximately 
30-fold less active than the parent drug, as evident from the 
in vitro studies. Another minor metabolite of paclitaxel is 
  3’-para-hydroxypaclitaxel, which is produced by cytochrome 
P450 3A4. These more polar metabolites penetrate the cells 
poorly, hence they are either inactive or much less cytotoxic 
than the parent compound.22,24,25
Dosing strategy for paclitaxel
Paclitaxel has been used in doses ranging from 60–250 mg/m2, 
over 1–96 hours and from 1–3 weekly intervals. However, no 
ideal dosing strategy for paclitaxel exists in ovarian cancer, 
even after almost two decades of its clinical use. Intense 
research efforts are underway to find the least toxic, least 
expensive, and most efficacious paclitaxel dosing strategy. 
Preclinical data suggested that prolonged exposure (96 hours) 
might have greater efficacy, but this was conclusively refuted 
by large prospective studies.26,27
Initial studies used arbitrarily selected 24-hour infu-
sions to reduce the risk of hypersensitivity reactions, but 
the development of effective premedication regimens led 
to evaluation of a broad range of more convenient dosing 
schedules (Table 1).28
In a landmark Canadian-European trial designed to find 
the best clinically relevant dose of paclitaxel, 407 patients 
were randomized to receive 175 or 135 mg/m2 of pacli-
taxel over either 24 or three hours in a 2 × 2 design. Major 
Table 1 Major studies with dose variations of paclitaxel in ovarian cancer (MOS and PFS in months unless otherwise indicated)
Study Agents/Schedule Eligibility n Response 
(%)
MOS 
(month)
PFS 
(month)
Comments
Spriggs et al27 
2007 GOG166
Paclitaxel 135 mg/m2/24 h + 
Cisplatin 75 mg/m2 vs 
Paclitaxel 120 mg/m2/96 h + 
Cisplatin 75 mg/m2
Suboptimal 
stage III 
or Iv
280 62 
70
2.5 yr 
2.5 yr
1 yr 
1 yr
Grade 4 neurotoxicity-
79% vs 54%  
Grade 3 anemia – 6% 
vs 18% Concluded that 
longer infusions are not 
better.
Omura et al31 
2003
Paclitaxel 135 or  
175 mg/m2/24 h vs  
Paclitaxel 250 mg/m2/24 h
Relapsed 
ovarian 
cancer
330 27 
36
12.3 
13.1
4.8 
5.5
Thrombocytopenia, 
neuropathy, and myalgia-
greater with 250 mg/m2 
dose, which exhibited 
a better response rate. 
But no survival benefit to 
justify paclitaxel  
250 mg/m2 + filgrastim.
Bolis et al30 2004 Paclitaxel 175 mg/m2 + 
Carboplatin AUC 6 vs 
Paclitaxel 225 mg/m2 + 
Carboplatin AUC 6
IIB-Iv 207 
219
64
56
4-year 
survival 
46% 
47%
4 year PFS 
42% 
39%
Concluded that  
175 mg/m2 preferred 
regimen.
Katsumata et al32 
2009
Paclitaxel 80 mg/m2/1h/wk × 
6 cycles + Carboplatin-AUC 
6/3 wks vs Paclitaxel  
180 mg/m2/3 h/3 wk ×  
6 cycles + Carboplatin AUC 
6/3 wks
II-Iv 631 56 
53
3-year 
survival 
72% 
65%
28 
17
Neutropenia 92% vs 88%. 
Grade 3/4 anemia 69% vs 
44%. Withdrawal because 
of toxicity – higher in 
dose-dense regimen 
than in the conventional 
regimen  
(n =113 vs n =69)
Abbreviations: AUC, area under curve; n, number; MOS, median overall survival; PFS, progression-free survival.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
414
Kumar et al
endpoints were the frequency of significant hypersensitiv-
ity reactions and objective response rate. This trial showed 
equivalent efficacy of the three-hour versus 24-hour infusion 
schedules for paclitaxel in recurrent ovarian cancer, with 
reduced bone marrow toxicity and an increased incidence 
of neuropathy with the shorter infusions.   Subsequently, the 
three-hour infusion schedule became the new standard due 
to its convenience and lesser cost compared with the other 
schedules.29 Furthermore, no clinically relevant advantage 
has been found with paclitaxel at a dose of 135 mg/m2 as 
compared with 225–250 mg/m2 in the setting of either 
upfront chemotherapy30 or relapsed disease.31 These 
observations paved the way for the concepts of weekly 
low-dose one-hour infusion and dose-dense paclitaxel.32 
These strategies are believed to reduce the risk of serious 
toxicity and alopecia markedly, with maintenance of   clinical 
efficacy.33
Katsumata et al recently reported a Phase III study of 
dose-dense paclitaxel in front-line ovarian cancer compar-
ing standard chemotherapy including paclitaxel 180 mg/m2 
over three hours every three weeks with a dose-dense regi-
men which included paclitaxel 80 mg/m2 over one hour 
every week in a three-week cycle. There was prolongation 
of progression-free survival (PFS), as well as median 
survival, in the dose-dense arm at the cost of a signifi-
cant increase in toxicity (Table 1).32 This study suggests 
that dose-dense paclitaxel may be of clinical benefit, but 
that toxicities must be mitigated before it can be adopted 
widely.34 Others have reported different doses on a weekly 
schedule as well.35–37 Suffice it to say that a weekly dosing 
strategy for paclitaxel in ovarian cancer remains under 
investigation.
Drug interactions
Because paclitaxel has saturable distribution and elimi-
nation at the currently used dosage, small changes in its 
pharmacokinetics could potentially cause serious effects, 
especially if the toxic effect is enhanced or, conversely, 
if the cytotoxic antitumor effect is diminished by drug 
interaction.
Interaction with other cytotoxic drugs
Cisplatin
The sequence of cisplatin 75 mg/m2 followed by paclitaxel 
infusion at 135 mg/m2 over 24 hours is associated with more 
profound neutropenia and less in vitro antitumor activity.38 
The hepatic clearance of paclitaxel may be decreased by 33% 
when it is preceded by cisplatin.38 The precise mechanism 
is unclear, but this could be caused by cisplatin-induced 
modulation of cytochrome P450 metabolism or damage to 
the kinestin heavy chain gene which plays a role in the cyto-
toxicity of many natural-based antitumor drugs.39 Sequence 
dependence is unlikely to be clinically relevant with shorter 
paclitaxel infusion schedules. Moreover carboplatin, the 
more commonly used platinum agent, does not appear to 
modulate cytochrome P450 systems or the pharmacokinetics 
of paclitaxel.40–42
Doxorubicin
Paclitaxel exhibits a sequence- and schedule-dependent 
interaction with doxorubicin.43 It increases the area under 
the curve (AUC) of doxorubicin by 30% when given 
before or immediately after doxorubicin and consequently 
increases the incidence of doxorubicin-induced cardio-
toxicity and myelosuppression, however, neither sequence 
of drug infusion significantly influenced the AUC of 
paclitaxel.43,44 Based on these observations, it was recom-
mended to restrict the cumulative dose of doxorubicin to 
360 mg/m2, to administer doxorubicin 24 hours before 
paclitaxel,43 and to use dexrazoxane with the combination 
as well.44
etoposide
Paclitaxel and etoposide exhibit schedule-dependent inter-
action and optimal synergism with sequential 24-hour use, 
without the impact of an intervening drug-free period. 
In contrast, less than additive inhibitory cytotoxicity is 
observed with concurrent administration of these agents 
in in vitro experiments.45 Other studies have reported 
independent antagonism with these two agents.46 However, 
the clinical relevance of these observations remains to be 
elucidated.
Topotecan
The sequential combination of paclitaxel and topotecan 
resulted in severe dose-limiting myelosuppression, although 
there is no established pharmacodynamic or pharmaco-
kinetic interaction between the two agents to explain this 
observation.43
Trastuzumab
In breast cancer patients, the incidence of congestive 
heart failure has been higher with the trastuzumab-
paclitaxel combination than with paclitaxel alone. Data 
are preliminary and the reason for this association is 
unknown.47International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Interaction with noncytotoxic drugs
The maximum tolerated dose of paclitaxel in cancer patients 
receiving anticonvulsant therapy, such as phenytoin and 
phenobarbital, is higher compared with those on no anti-
convulsant therapy (200 mg/m2 versus 140 mg/m2).48 This 
may be due to enhanced hepatic clearance which could 
result in reduction of the cytotoxic and antitumor effects of 
  paclitaxel.48 Explanation involves induction of cytochrome 
P450 mixed-function oxidases by the anticonvulsants.49
Paclitaxel in early ovarian cancer
The treatment strategy for early-stage ovarian cancer has 
evolved differently compared with that of late-stage dis-
ease, which is reflective of the higher relative prevalence 
and mortality of the latter compared with the former. Cur-
rently, the suggested treatment for early-stage ovarian cancer 
(FIGO I and II) in the US is optimal surgical staging followed 
by either chemotherapy or expectant management, depending 
on the stage and grade of the disease.50 Patients with Stage IA 
or IB disease with Grade I and II tumor have a greater than 
90% cure rate, and require no further postoperative treatment, 
while patients with a Stage I Grade 3 lesion or Stage II disease 
have a recurrence rate of approximately 25%–40% and will 
need additional postoperative chemotherapy.50 The duration 
of chemotherapy has been addressed by GOG protocol 157, 
where the investigators enrolled 427 stage I and II high-risk 
patients and compared three versus six cycles of paclitaxel 
at 175 mg/m2 for three hours plus carboplatin-AUC 7.5.51 
Both arms in the study had similar death rates, and the esti-
mated probability of recurrence within five years was 20.1% 
(six cycles) versus 25.4% (three cycles), respectively. The 
respective Grade 3 or 4 neurotoxicity was 11% versus 2%. 
Six cycles also caused significantly more severe anemia and 
granulocytopenia. In other words, this study showed a mini-
mal reduction in risk of recurrence, with a significant increase 
in toxicity due to the six cycles, and thus it is advocated for 
only three cycles of combination therapy in this setting. 
Several limitations of the study have been highlighted, and 
some continue to argue for the use of more chemotherapy 
in early-stage ovarian cancer, especially if the initial three 
cycles are tolerated without significant toxicity in patients 
with high-risk features.52 Also, a subsequent idea originating 
from this study was the GOG 175 protocol where the same 
patient population with high-risk, early-stage ovarian cancer 
is being randomized to either three cycles of carboplatin-
(AUC 6) with paclitaxel 175 mg/m2 or three cycles of the 
same regimen followed by weekly paclitaxel 40 mg/m2 for 
24 weeks. Results of this study are pending.
Paclitaxel in advanced ovarian 
cancer
Encouraged by successful completion of several Phase I trials 
safely administering paclitaxel and the subsequent response 
in other tumor types, several groups started using paclitaxel 
for ovarian cancer in Phase II trials.53–55 In the initial stud-
ies, an extremely high rate of hypersensitivity reactions of 
up to 30% was noted. To ameliorate this, longer infusion 
(24–96 hours)53,56 and pretreatment with antihistamine agents 
and steroids became necessary. These strategies, when used 
in combination, reduced the risk of severe hypersensitivity 
reactions to 5% or less, but marked the emergence of dose-
limiting neutropenia. It is noteworthy that some of the initial 
trials of paclitaxel included both platinum-sensitive as well 
as platinum-refractory patients, with response rates ranging 
from 20% to 37%.57,58
Due to the excellent response rates seen in these stud-
ies, the next logical step was to combine paclitaxel with 
platinum compounds, which are arguably the agents with the 
best   activity in ovarian cancer. Validating this notion was a 
Phase I study38 showing that paclitaxel and cisplatin could 
be given safely in combination, with paclitaxel administered 
first as a 24-hour infusion.
Subsequently, four major trials have been reported which 
compared platinum-paclitaxel doublets with other agents 
(Table 2). The first two of these (GOG 11159 and OV-1060) 
helped to establish platinum-paclitaxel as front-line therapy 
in ovarian cancer, whereas the subsequent two trials (GOG 
13261 and ICON362) have questioned whether the addition of 
paclitaxel to platinum provides any additional benefit.
In GOG 111, a cyclophosphamide-cisplatin doublet was 
compared with paclitaxel-cisplatin in patients with stages III 
and IV ovarian cancer. The authors reported a response 
rate of 60% versus 73%, a PFS of 13 versus 18 months, 
and median survival of 24 versus 38 months, respectively, 
favoring the paclitaxel-cisplatin doublet compared with the 
cyclophosphamide-cisplatin doublet. On the other hand, 
OV-10 showed an overall survival of 26 versus 36 months 
and a PFS of 12 versus 16 months (P , 0.05), both favoring 
the paclitaxel-cisplatin doublet (Table 2).
In GOG 132, 648 suboptimally debulked stage III and 
IV epithelial ovarian cancer patients were randomized to 
receive cisplatin or paclitaxel or the combination of pacli-
taxel-cisplatin. This trial concluded that cisplatin alone or 
in combination yielded superior response rates and a PFS 
relative to paclitaxel. However, the OS (overall survival) 
was similar in all three arms, and the combination therapy 
had a better toxicity profile. Therefore, the authors argued International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Phase III trials of paclitaxel and platinum compounds in front-line chemotherapy for advanced ovarian cancer
Study Agents/Schedule Eligibility (Stage) n Response 
(%)
MOS  
(months)
PFS  
(months)
Comments
McGuire et al59 
1996  
GOG-111 
Paclitaxel 135 mg/m2/24 h +  
Cisplatin 75 mg/m2; six cycles vs  
Cyclophosphamide 750 mg/m2 +  
Cisplatin 75 mg/m2; six cycles
Suboptimal III, Iv 386 73 vs 60 38 
24
18 
13
Piccart et al60  
2000  
Ov-10 
Paclitaxel 135 mg/m2/3 h +  
Cisplatin 75 mg/m2 vs  
Cyclophosphamide 750 mg/m2 +  
Cisplatin 75 mg/m2
Optimal or 
suboptimal IIB–Iv
680 59 vs 45 36 
26
16 
12
Neurotoxicity   
19% vs 1%
Muggia et al61  
2000  
GOG132 
Paclitaxel 135 mg/m2/24 h +  
Cisplatin 75 mg/m2 vs paclitaxel  
200 mg/m2/24 h vs cisplatin  
100 mg/m2 
Suboptimal III,  
Any Iv
614 67 vs 42  
vs 67
26 
26 
30
14 
11 
16
ICON362 2002  Paclitaxel 175 mg/m2/3 h + 
Carboplatin AUC 6 vs CAP or 
Carboplatin 
I–Iv 2075  NA 36 
35
17 
16
Abbreviations: AUC, area under curve; n, number; CAP, cyclophosphamide-doxorubicin-cisplatin combination; MOS, median overall survival (in months unless otherwise 
indicated); PFS, progression free survival (in months unless otherwise indicated).
that the cisplatin-paclitaxel combination should remain the 
preferred initial treatment option. Perhaps the best rationale 
for lack of observed superior response with the platinum-
paclitaxel doublet was the inclusion of a suboptimal control 
arm due to more than half of the patients in the single-agent 
arms crossing over to the other agents subsequently on a 
nonprotocol basis.61
The results of ICON3 were reported in 2002 in 
which paclitaxel-carboplatin versus carboplatin or 
cyclophosphamide-doxorubicin-cisplatin (CAP) were 
compared. No   difference was found in OS between the 
paclitaxel-carboplatin and control groups. The trial concluded 
that single-agent carboplatin and CAP are as effective as the 
paclitaxel-carboplatin doublet. Also, the favorable toxicity 
profile of single-agent carboplatin suggested that this drug 
may be a reasonable option as first-line chemotherapy for 
ovarian cancer.62 This trial called into question the additional 
benefit offered by paclitaxel over the platinum compounds, 
but was not successful in changing the practice on a large 
scale in patients due to several limitations which are analyzed 
by Sandercock et al in detail.63
Several theoretical arguments support the concurrent use 
of paclitaxel with platinum in ovarian cancer. Firstly, addition 
of a second agent may be useful in reducing the possibility of 
development of resistant clones. Secondly, a greater cell kill 
might be achieved at the start of the treatment, which may 
mean a higher proportion of patients becoming tumor-free 
at induction chemotherapy. Thirdly, the dual agent approach 
may help to lower the doses, and hence the toxicity of each 
of the single agents involved, and still preserve acceptable 
efficacy. Support for these notions comes from a meta-
analysis in which the platinum-paclitaxel doublet still had 
an edge over the other agents.63 Consequently, platinum and 
paclitaxel remain the preferred front-line chemotherapy for 
ovarian cancer in the US.
Due to the significant side effects of cisplatin, including 
nausea/vomiting, neurotoxicity, and nephrotoxicity, several 
trials have looked at substituting cisplatin with carboplatin, 
a better tolerated platinum compound. A study by Neijt 
et al64 compared paclitaxel at 175 mg/m2 for three hours 
with cisplatin or carboplatin, and a study by du Bois et al65 
compared paclitaxel at 185 mg/m2 with either cisplatin or 
carboplatin as front-line chemotherapy in ovarian cancer. 
Both these studies showed similar response rates, PFS, and 
OS in the cisplatin and carboplatin arms. Similar findings 
were reported by Ozols et al in a GOG study.66 As expected, 
more gastrointestinal and neurologic toxicity was found in 
patients receiving cisplatin and more myelosuppression in 
patients randomized to carboplatin, but overall, the latter 
resulted in lesser toxicity, more convenient dosing, and no 
inferiority when compared with the former agent. Hence, 
intravenous (IV) carboplatin has replaced IV cisplatin in 
clinical practice around the world.
Paclitaxel in recurrent ovarian 
cancer
Approximately two-thirds of patients will respond to front-
line chemotherapy in ovarian cancer, but the majority of 
these women will have disease recurrence. Cure is rare and, 
therefore, the goals of treatment in recurrent ovarian cancer International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 3 Major trials employing a third agent with the paclitaxel-carboplatin doublet
Study Schedule/Agents n PFS/MOS Comments
du Bois et al102 TEC arm  
Paclitaxel 175 mg/m2+ carboplatin 
AUC-5 + epirubicin 60 mg/m2 
every 3 wks x 6 cycles vs  
Paclitaxel 175 mg/m2 + carboplatin AUC-5 
every 3 wks × 6 cycles
1282 18/46  
 
 
 
18/41
Grade 3–4 hematological toxicities and 
grade 3–4 febrile neutropenia-more 
frequent in the first group. Nausea, 
vomiting, stomatitis/mucositis and 
infections-significantly less frequent in  
the second group. Inferior quality of life in 
TeC arm
Scarfone et al103 Paclitaxel 175 mg/m2 D1 
Carboplatin AUC-5 D1 
Topotecan 1 mg/m2 D1–3 
every 3 weeks for 6 cycles vs 
Paclitaxel 175 mg/m2 D1 
Carboplatin AUC-5 D1 
every 3 weeks for 6 cycles
326 Median PFS 
72 vs 70 weeks
Grade ¾ neutropenia 40% vs 24%. 
Alopecia 72% vs 78.2% and nausea/
vomiting 51% vs 44%
GOG182-ICON5104 
Phase III
ARM 1 Control 
Paclitaxel 175 mg/m2 D1 
Carboplatin AUC 6 D1 
every 3 wks for 8 cycles
ARM 2 Gemcitabine triplet 
Paclitaxel 175 mg/m2 D1 
Carboplatin AUC 5 D1 
Gemcitabine 800 mg/m2 D1,8 
every 3 wks for 8 cycles.
ARM 3 Doxil triplet 
Paclitaxel 175 mg/m2 D1 
Carboplatin AUC 5 D1 
Doxil 30 mg/m2 (cycle 1, 3, 5, 7) 
every 3 wks for 8 cycles.
ARM 4 Topotecan doublet 
Carboplatin AUC 5 D3 (Cycle 1–4) 
Topotecan 1.25 mg/m2/day D1–3 (cycle 1–4) 
Paclitaxel 175 mg/m2 in 3 h D1(cycle 5–8) 
Carboplatin AUC 6 D1(cycle 5–8)
ARM 5 Gemcitabine doublet 
Carboplatin AUC 6 D8 (cycle 1–4) 
Gemcitabine 1000 mg/m2/day D1–8 (cycle 1–4) 
Paclitaxel 175 mg/m2 in 3 h D1(cycle 5–8) 
Carboplatin AUC 6 D1(cycle 5–8)
4412 No significant 
difference in the 
PFS and OS
Increased hematologic toxicity with triplet 
regimens. Increased thrombocytopenia 
with gemcitabine. Neuropathy decreased 
in doublet group which included only four 
cycles of Paclitaxel.
Penson et al105 
Phase II
Paclitaxel 175 mg/m2 in 3 h-cycle 1–6 
Carboplatin AUC 6 cycle 1–6 
Bevacizumab 15 mg/kg in cycle 2–6 then 
continued for 1 year
62 PFS at 36 months 
58%. Radiographic 
response rate 75%
2 cases of pulmonary embolism and 2 of 
GI perforations.
Micha et al106 
Phase II
Paclitaxel 175 mg/m2 in 3 h-cycle 1–6 
Carboplatin AUC 6 cycle 1–6 
Bevacizumab 15 mg/kg cycle 2–6
20 80% Overall response Grade 3 and 4 neutropenia 23% and 25% 
cycles. No GI perforation, 2 cases of  
grade 3 hypertension and 2 cases of DvT
Abbreviations: AUC, area under curve; DvT, deep vein thrombosis; MOS, median overall survival (in months unless otherwise indicated); n, number; PFS, progression-free 
survival (in months unless otherwise indicated); TeC, paclitaxel-etoposide-cyclophosphamide combination; GI, gastrointestinal.
are maintaining an acceptable quality of life, control of 
symptoms, and prolonging survival, if possible.67
It has been established that a longer time interval to 
relapse after the initial platinum-based therapy (the plati-
num-free interval) was associated with a higher response 
rate to retreatment with platinum as well as other drugs.68,69 
Accordingly, patients who relapsed within six months of 
completing initial platinum-based therapy were classified 
as platinum-resistant whereas those who relapsed after six 
months were considered to be platinum-sensitive.
In addition to platinum and taxanes, several agents 
have shown activity in relapsed ovarian cancer, including 
bevacizumab,70 altretamine (hexamethylmelamine),71 lipo-
somal doxorubicin,72,73 topotecan,74,75 gemcitabine,76–78 oral 
etoposide,79,80 ifosfamide,81 navelbine, capecitabine, tamox-
ifen, and pemetrexed. Research in this area continues to grow International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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as more anticancer agents are discovered. Whereas the best 
response rates in platinum-resistant patients have been in 
the 10%–20% range, response rates for platinum-sensitive 
disease have generally been much higher.
Paclitaxel in platinum-sensitive 
recurrence
Studies in platinum-sensitive patients can be classified into 
one of three groups, ie, non-platinum single-agent treat-
ment, non-platinum combinations, and platinum-containing 
  combinations (see Table 4A). In 1997 ten Bokkel Huinink 
et al published a trial82 comparing topotecan with paclitaxel 
and did not find significant differences between the two 
groups for response rates or survival.83 However, paclitaxel 
was much less toxic to bone marrow than topotecan. The 
European Organisation for Research and Treatment of Cancer 
(EORTC) randomized 86 women to either single-agent pacli-
taxel or oxaliplatin. Response in the 63 platinum-resistant 
group was 16% versus 6% in the paclitaxel versus oxaliplatin 
arms, respectively, and for the platinum-sensitive group was 
20% versus 38%, respectively.84
In one Phase II study of a platinum-free interval (PFI) 
.12 months, paclitaxel 175 mg/m2 IV over three hours 
was compared with the CAP regimen. Although the 
overall response rates were similar, CAP was associated 
with significant increases in response duration (16 versus 
9 months) and median survival (35 versus 26 months). The 
authors concluded that single-agent paclitaxel may not be 
as active as platinum-based chemotherapy in recurrent 
ovarian cancer.85
A body of evidence supports the use of a platinum-
paclitaxel doublet in women with platinum-sensitive 
relapse. Although the best response is seen in patients 
with a PFI of .24 months, response rates as high as 
60% and a complete response rate of up to 25% may be 
achieved. A retrospective study of patients treated with 
paclitaxel-carboplatin reported a response rate of 84%. 
The PFS and OS were 9.7 and 13.1 months, respectively.86 
In a Phase II study, the Spanish Ovarian Cancer Research 
Group (GEICO) compared carboplatin with the paclitaxel-
carboplatin doublet. With no significant difference in 
Grade 3–4 hematologic toxicity, the response rate favored 
Table 4A Paclitaxel in platinum-sensitive recurrent ovarian cancer
Study Agent/Schedule n Response (%) Comments
ten Bokkel  
Huinink et al82,83
Topotecan (1.5 mg/m2) as a 30-minute 
infusion daily for 5 days q21 days vs 
paclitaxel (175 mg/m2)/3 h q21 days
226 20.5 vs 13.2  
(P = 0.138)
Neutropenia was significantly more 
frequent on the topotecan arm 
79% vs paclitaxel arm 23%  
(P , 0.01). Median survival 63 vs 
53 weeks
Piccart et al84 Paclitaxel at 175 mg/m2/3 h  
q3 weeks, vs oxaliplatin at 130 mg/m2/  
2 h q3 weeks
86 20 vs 38 for sensitive disease 
16 vs 6 for resistant disease
Neutropenia 22% vs none 
Neurotoxicity 7% vs 9%
Cantu et al85 Paclitaxel 175 mg/m2 Iv/3 h  
q3 weeks vs cyclophosphamide, 
Doxorubicin, and cisplatin (CAP)
97 45 vs 55 Leukopenia 4% vs 34%, neutropenia 
13% vs 36% MOS 25.8 vs 34.7 months 
(P , 0.043)
Buda et al89 epidoxorubicin + paclitaxel 175/3 h, 
q21 days for 4–6 cycles vs paclitaxel  
175 mg/m2/3 h, q21 days for  
4–6 cycles
212 37 vs 47 Neutropenia: 37% vs 18%
Pujade-Lauraine et al 
2009 ASCO CALYPSO 
study
Carboplatin with PLD vs carboplatin 
with paclitaxel
976 NA PFS 11 vs 9 months, P , 0.05 PLD 
arm had fewer infusion reactions, less 
alopecia and less chronic neurotoxicity
Gronlund et al86 Paclitaxel (175 mg/m2)/3 h followed by 
carboplatin AUC 5, q3 weeks
241 84 Retrospective MOS 13.1; PFS 9.7
Gonzalez-Martin et al87 Carboplatin AUC 5 vs paclitaxel  
175 mg/m2 + carboplatin AUC 5
81 50 vs 76 No differences in hematological 
toxicity. Mucositis, myalgia/arthralgia 
and peripheral neuropathy were more 
frequent in combination therapy.
Parmar et al88 Paclitaxel 175–185 mg/m2 + cisplatin 50 
mg/m2/carboplatin AUC 5–6 vs cisplatin 
75 mg/m2/carboplatin  
AUC 5–6
802 78 vs 69 P = 0.06 MOS 29 vs 24
Abbreviations: AUC, area under curve; CAP, cyclophosphamide-doxorubicin-cisplatin combination; Iv, intravenous; MOS, median overall survival (in months unless 
otherwise indicated); n, number; NA, not applicable; PFS, progression free survival (in months unless otherwise indicated); PLD, pegylated liposomal doxorubicin.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 4B Paclitaxel in platinum-resistant recurrent ovarian cancer
Study Agent/Schedule n Response (%) Comments
McGuire et al91 Paclitaxel 110 to 250 mg/m2/24 h  
q22 days
40 total 
25 resistant
24 Myelosupression dose limiting 
toxicity; 2 fatal cases of sepsis.
Thigpen et al57 Paclitaxel 170 mg/m2/Iv/24 h/q3 weeks 43 total 
27 resistant
33 Neutropenia 73%
Trimble et al143 Paclitaxel 135 mg/m2/Iv/24 h/q3 weeks 652 22 Leucopenia 78% fever 33%, 
infection 12%.
Markman et al93  Weekly paclitaxel 80 mg/m2 53 25 5 patients dropped due to 
toxicity, 4 due to peripheral 
neuropathy, and 1 because of 
painful fingernail beds
Markman et al94  Weekly paclitaxel 80 mg/m2 48 21 Grade 3 neuropathy: 4%; grade 
3 fatigue: 8%
Kita et al95 Paclitaxel 80 mg/m2/week in 1-h infusion,  
3 weeks on, 1 week off, and 
repeated at least twice
37 total 
14 resistant
29 Neutropenia 24%
Kaern et al96 Weekly paclitaxel 80 mg/m2/h infusion 57 56 Grade 2 neutropenia 2 patients
Rosenberg et al97 Weekly paclitaxel 67 mg/m2 vs 3 weekly 
Paclitaxel 200 mg/m2
208 Similar efficacy  
in two arms
Grade 3–4 hematological and 
non-hematological toxicity 
occurred more frequently in  
3-weekly arm
Havrilesky et al98  Carboplatin AUC 2 and paclitaxel at  
80 mg/m2 on days 1, 8, and 15 on a  
28-day cycle
28 Total 
8 Resistant
38 Neutropenia 32%
Abbreviations: AUC, area under curve; Iv, intravenous.
the platinum-paclitaxel doublet (75.6% and 50%).87 The 
best evidence yet in favor of using a platinum-paclitaxel 
doublet for platinum-sensitive relapse comes from the 
ICON4 trial where 802 patients with platinum-sensitive 
relapse were randomized to paclitaxel-platinum or single-
agent platinum. The trial showed a two-year survival rate 
of 57% versus 50%, favoring the combination (hazard ratio 
0.82; 95% confidence interval [CI] 0.69–0.97, P = 0.02). 
There was a higher incidence of Grade 2–4 neurologic 
effects (20% versus 1%), alopecia (86% versus 25%), and 
a lower rate of myelosuppression in the paclitaxel-treated 
patients.88
An Italian trial compared an epidoxorubicin-paclitaxel 
doublet with paclitaxel alone and favored the latter based 
on a better response rate.89 More recently, the CALYPSO 
study compared carboplatin plus either pegylated liposomal 
doxorubicin (PLD) or paclitaxel in 976 women with relapsed 
platinum-sensitive disease. In preliminary findings pre-
sented at the 2009 ASCO meeting,90 PLD-carboplatin was 
not inferior to paclitaxel-carboplatin, was associated with 
a significant prolongation in PFS (11.3 versus 9.4 months), 
and was less toxic. The investigators concluded that PLD-
carboplatin could be considered a valid alternative to 
carboplatin-  paclitaxel for treatment of platinum-sensitive 
disease.
Paclitaxel in platinum-resistant 
disease
Single-agent taxanes have produced response rates in the 
20% range for platinum-resistant disease in Phase II and III 
studies57,58,91,92 (see Table 4B). There is no agreement on the 
optimal schedule and dose of paclitaxel in recurrent ovarian 
cancer. In one trial, doses of 135 to 175 mg/m2 every three 
weeks, either as a three-hour or 24-hour infusion, showed 
similar response rates. Three-hour infusions were associ-
ated with more neurotoxicity but less myelosuppression.29 
Others have used higher doses of paclitaxel in the Phase III 
setting (250 versus 175 mg/m2 per dose) with hematopoietic 
growth factor support and reported higher response rates, 
and significantly more thrombocytopenia, neuropathy, and 
myalgia, but no improvement in survival with the higher 
dosage (P , 0.05).31 Thigpen et al used longer infusions 
of paclitaxel at 170 mg/m2 IV once over 24 hours every 
three weeks, and reported Grade 4 neutropenia in 73%.57 
Weekly paclitaxel may maintain antitumor efficacy while 
minimizing toxicity, especially myelosuppression. This 
concept has been tested by several studies in the setting 
of relapsed ovarian cancer. Markman et al reported two 
Phase II studies of weekly paclitaxel with response rates of 
20%–25%.93,94 In the first study, five of 53 patients discon-
tinued therapy because of toxicity (four due to peripheral International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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neuropathy and one due to painful fingernail beds).93 In 
the second study, serious adverse events were relatively 
uncommon.94   Similarly, Kita et al used weekly paclitaxel 
by hourly   infusion, with a 29% response in the platinum-
resistant setting. They reported Grade 3 or 4 neutropenia 
in 24% of their patients but there were no hospital admis-
sions for neutropenic fever.95 In another study, 57 patients 
were treated with weekly paclitaxel with a response rate 
of 56%, a median PFS of five months, and median OS of 
13.7 months. Only two patients had Grade 2 neutropenia, 
and no neutropenic fever was   recorded.96   Rosenberg et al 
compared three-weekly paclitaxel with one-third of the 
total dose used per week, the goal being to have similar 
total doses of paclitaxel in both arms of the trial. There 
was no difference in efficacy between the two arms, but 
less toxicity (other than fingernail toxicity) was observed 
in the weekly arm.97 In an innovative study of combination 
chemotherapy, Havrilesky et al used a reduced dose of 
carboplatin-paclitaxel on a weekly basis. In this study, eight 
platinum-refractory patients had a response rate of 37.5%, 
while 21 platinum-sensitive patients had a 100% response 
rate. Major toxicity in the form of Grade 3 neutropenia was 
seen in 32% of patients.98
Paclitaxel maintenance therapy
A randomized trial of 12 versus three months of maintenance 
paclitaxel at 175 mg/m2 over three hours every 28 days in 
277 women after a complete response to initial therapy 
improved PFS (28 versus 21 months), but no difference in OS 
was observed either in the initial report or subsequent updates 
of the data. This study was stopped early by the Data Monitor-
ing Committee when approximately half the proposed accrual 
had occurred due to the observed benefit in PFS, which was 
the proposed endpoint of the study. It was speculated that 
the lack of difference in the OS was due to underpowering 
of the study due to its early closure. In addition, treatment at 
relapse might have equalized the outcome. It is also notewor-
thy that the initial dose of paclitaxel was reduced in the trial 
from 175 to 135 mg/m2. The overall Grade 2/3 neuropathy 
rate in the trial was 14% and 18% in the control and treatment 
groups, respectively.99,100 In contrast, an Italian study reported 
by Pecorelli et al in 2009 randomized 200 women after initial 
complete response to either observation (ie, control) or six 
courses of paclitaxel 175 mg/m2 every three weeks and found 
no difference in PFS or OS.101
The GOG 212 trial is in progress comparing 12 cycles of 
paclitaxel versus 12 cycles of paclitaxel poliglumex   versus 
observation until documented relapse, after a complete 
response to front-line therapy is achieved. This trial will 
hopefully resolve the controversy relating to the benefit of 
maintenance therapy.
Addition of a third agent  
to carboplatin-paclitaxel
Recently, several groups have tried to add a third agent 
to the paclitaxel-carboplatin doublet to exploit any poten-
tial clinical benefit. Du Bois et al added epirubicin and 
reported no benefit,102 whereas Scarfone et al added topo-
tecan without any clinical benefit.103 In a landmark study 
of collaborative management of clinical trials, the GOG 
182/ICON5 reported no evidence of clinical benefit from 
addition of topotecan, gemcitabine, or liposomal doxorubicin 
in the front-line treatment setting.104 However, encouraging 
results have been reported with addition of bevacizumab, 
the humanized monoclonal antibody against vascular 
endothelial growth factor. Two small Phase II trials reported 
good results and manageable toxicities.105,106 The “litmus 
test” of bevacizumab addition will be provided by GOG 
218 and ICON7. GOG 218 is a randomized, double-blind, 
placebo-controlled, multicenter study, which is evaluating the 
paclitaxel-carboplatin doublet ± bevacizumab, either for six 
courses or for 22 courses (http://clinicaltrials.gov/ct/show/
NCT00262847). ICON7 is testing a similar hypothesis, but 
the dose and duration of bevacizumab are different. This 
study finished recruiting 1528 patients in February 2009 and 
the results are pending.
Paclitaxel in intraperitoneal 
chemotherapy
Intraperitoneal (IP) spread presents one of the main routes of 
metastasis in epithelial ovarian cancer. Hence, the delivery of 
IP chemotherapy has always held theoretical promise, which 
investigators have tried to explore in at least three major 
randomized trials, two of which included paclitaxel.
Alberts et al107 reported a trial of IV cisplatin-cyclophos-
phamide compared with IP cisplatin-cyclophosphamide, 
with a survival benefit in the IP arm of the study 
(41 versus 49 months). The main limitation of this study is 
that it preceded the paclitaxel era, and thus did not reflect 
contemporary therapy. Interestingly, the subset of patients 
with the lowest volume of disease did not demonstrate benefit 
from the IP approach.
In 2001, Markman et al108 reported a second major trial 
of 462 patients randomized to receive either IV paclitaxel 
135 mg/m2 over 24 hours followed by IV cisplatin 75 mg/m2 
every three weeks for six courses or IV carboplatin-AUC 9 International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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every 28 days for two courses, then IV paclitaxel 135 mg/m2 
over 24 hours followed by IP cisplatin 100 mg/m2 every 
three weeks for six courses. This study reported a survival 
advantage in the IP arm (52.5 versus 63.2 months). This 
study has been criticized on the basis that more chemo-
therapy, rather than the IP route, may have resulted in 
the benefit because the patients in the IP arm received IV 
carboplatin-AUC 9 for two cycles before the IP therapy, 
representing a significant difference from the regimen used 
in the standard arm.
In January 2006, Armstrong et al published the results 
of GOG 172109 in which patients with optimally debulked 
Stage III ovarian carcinoma were randomly assigned to 
receive 135 mg/m2/24 hours of IV paclitaxel followed 
by either 75 mg/m2 of IV cisplatin or 100 mg/m2 of IP 
cisplatin on day 2 and 60 mg/m2 of IP paclitaxel on day 
8 (IP group). Treatment was given every three weeks 
for six cycles. Although only 42% of the patients in the 
IP arm completed six cycles of the assigned therapy. 
The median PFS was 18.3 versus 23.8 months, and the 
median OS was 49.7 versus 65.6 months, favoring the IP 
arm. Note that in this trial, the experimental arm used 
24-hour IV paclitaxel followed by IP cisplatin on day 2 
and IP paclitaxel on day 8. The added day 8 paclitaxel 
regimen introduces another set of variables in addition to 
the mode of delivery of the therapy. Some argue that the 
results seen with GOG 172 are not significantly better 
than what can be achieved with the IV carboplatin and 
three-hour paclitaxel regimens.110–112 It is noteworthy that 
neutropenia, gastrointestinal toxicity, fatigue, pain, and 
metabolic events were increased in the IP arm. In addi-
tion, quality of life was significantly worse in the IP arm 
while on therapy but improved at the one-year follow-up. 
In addition, IP chemotherapy catheters caused abdominal 
pain, nausea, vomiting, infection, and fever.
On the basis of findings of increased survival with IP 
therapy in these three studies, the NCI issued a clinical 
advisory notice that recommended IP therapy be considered 
for women with ovarian cancer. Apart from the fact that IP 
therapy is more toxic, no IP regimen has so far been compared 
with what many consider to be the current standard, ie, IV 
carboplatin and paclitaxel.112,113
Resistance to paclitaxel
Several mechanisms have been described to explain resis-
tance to paclitaxel. The foremost are increased expression of 
the efflux transporter Pgp, multidrug resistance-  associated 
  protein 2, and decreased expression of the influx   transporter, 
ie, the organic anion transporting polypeptide 1 B3 
(OATP1B3/SLCO1B3).24 Other possible mechanisms include 
overexpression of the paclitaxel-metabolizing enzyme 
CYP2C8,30 hypo-stable microtubules, mutations in tubulin 
that alter binding of paclitaxel, and alteration in the signal-
ing pathways associated with microtubule function.21,24 
Kavallaris et al demonstrated that resistance of epithelial 
ovarian cancer cell lines to paclitaxel is correlated with 
increased levels of Class I, III, and IVa B-tubulin isotypes.114 
HER2/neu  (c-erbB2) overexpression has also been   implicated 
in paclitaxel resistance.115,116
MDR phenotype, which can be mediated by several 
multidrug transporters, particularly the 170-kDa Pgp efflux 
pump encoded by the mdr1 gene, structurally altered α- and 
β-tubulins, and an impaired ability to polymerize tubulin 
dimers into microtubules. For example, high levels of the 
βIII isotype, a minor component of cellular β-tubulin that 
increases the dynamic instability of microtubules, impairs 
rates of microtubule assembly, and increases resistance to 
taxanes.117–119
Toxicity
Hematologic
The major adverse effect of paclitaxel is myelosuppression, 
which mainly consists of neutropenia, whereas thrombocy-
topenia and anemia are uncommon.120 Neutropenia is more 
profound with higher doses, prolonged infusion, or if prior 
myelosuppressive therapy was used (eg, paclitaxel given after 
cisplatin). In the European-Canadian trial, the incidence of 
myelosuppression was 71% and 18% with 24-hour and 3-hour 
infusion, respectively, while febrile neutropenia was docu-
mented only in patients who received the 24-hour   infusion.29 
The neutropenia begins a week after paclitaxel infusion, 
nadirs in the second week, with complete recovery by the 
third week. Neutropenia does not reach lower levels with 
subsequent cycles, suggesting that toxicity is noncumulative. 
Paclitaxel has a platelet-sparing effect on thrombocytopenia 
produced by carboplatin.121 It is believed that clinically rel-
evant doses of paclitaxel can be given without bone marrow 
supporting agents.122
Hypersensitivity reactions
Historically, the incidence of major hypersensitivity reac-
tions to paclitaxel approached 30%, but the incidence is 
down to 1% to 3% following widespread prophylactic use 
of steroids and antihistamine pretreatment. The vast majority 
of these events are minor (dyspnea, bronchospasm, urticaria, 
hypotension, rash, and itching). They typically occur within International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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the first 10 minutes after the first or second cycle, respond 
well to supportive measures, and do not require cessation 
of therapy. Major reactions on the other hand are generally 
severe, eg, anaphylaxis, angioedema, or shock, and require 
cessation of therapy followed by emergent treatment. 
  Usually, minor reactions do not indicate development of a 
major event. The hypersensitivity reactions are most likely 
caused by the polyoxyethylated castor oil vehicle, but the 
taxane moiety may also be contributory. It is noteworthy 
that in one large trial the incidence of major events was 
reported to be similar, irrespective of the infusion schedule 
used.29 Evidence   suggests that the vast majority of patients 
may be successfully retreated with slow, low-dose infu-
sions of paclitaxel after premedication with appropriate 
desensitization schedules. Markman et al reported a 100% 
success rate with taxane rechallenge in 44 patients with 
their regimen.123
Neuromuscular
In contrast with myelosuppression, peripheral neuropathy 
is cumulative and progressive with increasing exposure to 
the drug, but usually disappears several weeks or months 
after discontinuation of paclitaxel. Neuropathy due to 
paclitaxel presents as numbness and paresthesia in a glove-
and-stocking distribution. It is usually symmetric, sensory as 
well as motor, and affects proprioception, vibration, tempera-
ture, and pinprick sensation. The time of onset is typically 
several weeks at conventional doses (135 to 250 mg/m2), and 
quicker (24–72 hours) at higher doses (.250 mg/m2). The 
most commonly affected sites include the limbs, face (perio-
ral numbness), optic nerve (scintillating scotoma), joints, and 
the autonomic nervous system. Risk factors include longer 
treatment, higher doses, alcohol, diabetes, and preexisting 
neuropathy. Transient muscle pains are common, and frank 
myopathy may occur at doses higher than 250 mg/m2 or 
in combination with platinum agents. Unlike hematologic 
  toxicity, neuropathy is observed more frequently with shorter 
infusion schedules (less than three hours).
The management of paclitaxel-induced neuropathy is a 
matter of intense research. Although multiple agents have 
been proposed to ameliorate nerve damage, few have been 
studied, and with mixed results. Amitriptyline and gabapentin 
have been used in neuropathic pain with success. Neuropro-
tective agents in the form of high dose vitamin E, glutamine, 
lamotrigine, and disodium 2,20-dithio-bisethanesulfonate 
(BNP7787, which is reduced to mesna) all have preliminary 
data in their support but await large-scale trials to validate 
their widespread use.124
Cardiac
In the initial clinical trials of paclitaxel, routine cardiac 
monitoring was performed due to a high rate of hypersen-
sitivity reactions. This led to the detection of a relatively 
high rate of cardiac rhythm disturbances, the relevance 
of which is   doubtful because the vast majority of patients 
remained asymptomatic. Therefore, routine cardiac moni-
toring of patients receiving paclitaxel is no longer required. 
  Nevertheless, the most common rhythm disturbance appears 
to be asymptomatic transient bradycardia. Mobitz Type I 
  (Wenckebach phenomenon), Mobitz Type II, and   third-degree 
heart block have also been noted, but the   incidence in a large 
NCI   database was only 0.1%.125
There is no evidence that chronic paclitaxel use causes 
cardiac dysfunction. However, cardiac monitoring should 
be considered for patients with atrioventricular conduction 
disturbances or ventricular dysfunction. Doxorubicin used 
with paclitaxel increases cardiac toxicity more than what 
would be expected with the former alone. Dexrazoxane 
may help reduce cardiotoxicity in this setting but the data 
remain preliminary.126–129 In a Phase III trial of trastuzumab-
paclitaxel in breast cancer, the incidence of cardiotoxicity was 
increased, warranting careful patient monitoring.130
Gastrointestinal
Paclitaxel-induced gastrointestinal effects are generally 
uncommon and limited to mild nausea, mucositis, diarrhea, 
and elevated liver function tests, so routine use of antiemetics 
is not recommended. Rare cases of neutropenic enterocolitis, 
gastrointestinal necrosis,131 typhlitis,132 hepatotoxicity,133 
and pancreatitis134 have been reported, especially with high 
doses of paclitaxel in combination with doxorubicin or 
cyclophosphamide.
Dermatologic
Paclitaxel induces reversible alopecia of the scalp. Extrava-
sations of large volumes can cause moderate soft tissue 
injury, and rare reports of nail disorders and recall reactions 
at previously irradiated sites have also been noted, although 
mostly with weekly schedules only.23
Newer forms of paclitaxel
Several newer forms of paclitaxel have been manufac-
tured, aimed at decreasing toxicity, increasing efficacy, and 
improving ease of administration. Abraxane® is an albumin-
bound form of paclitaxel which delivers paclitaxel as a sus-
pension of albumin nanoparticles in saline, eliminating the 
need for Cremophor EL, the traditional carrier for the drug. International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Cremophor EL is considered a key factor in hypersensitivity 
reactions to paclitaxel, leading to slower infusion rates and a 
need for premedication. Abraxane may eliminate these limi-
tations and offers the additional advantages of delivery of a 
relatively higher dose of paclitaxel. Fader et al successfully 
treated five patients with severe hypersensitivity reactions to 
traditional paclitaxel with 80 to 100 mg/m2 of Abraxane in 
gynecologic cancers.135
Abraxane may also increase intratumoral concen-
tration of paclitaxel by a receptor-mediated transport 
process across the endothelial cell wall, thereby breach-
ing the blood/tumor interface.136 Although Abraxane has 
  demonstrated a high degree of activity in metastatic breast 
and lung cancer,137,138 its toxicity profile and response rates in 
ovarian cancer remain to be elucidated in a large number of 
patients. In a Phase II study, Teneriello et al treated patients 
with recurrent platinum-sensitive disease using Abraxane 
260 mg/m2 for 30 minutes on day 1 of a 21-day cycle for 
six cycles or until disease progression. The response rate 
was 64% (15 complete and 13 partial responses among 44 
assessable patients). Estimated median PFS was 8.5 months. 
The most frequent Grade 3–4 toxicities were neutropenia 
(24%) and neuropathy (9%).139 Several other trials of this 
formulation are in progress.
Taxoprexin® is paclitaxel bound to docosahexaenoic 
acid (DHA), a fatty acid that is easily taken up by tumor 
cells. Upon entry of this prodrug into the cell, normal 
metabolism cleaves the fatty acid moiety to yield the active 
drug. The main advantage of DHA-paclitaxel is its ability 
to carry much higher concentrations of paclitaxel to the 
cells.140
Paclitaxel poliglumex is a conjugate of paclitaxel and 
poly-L-glutamic acid which accumulates in tumor tissue 
due to enhanced permeability of the tumor vasculature and 
lack of lymphatic drainage. Paclitaxel poliglumex prolongs 
exposure to the active drug and minimizes systemic   exposure. 
In a Phase II GOG study of relapsed ovarian cancer, a 
response rate of 16% was seen, with Grade 3 and 4 toxicities 
being neutropenia (24% and 20%, respectively), constitu-
tional symptoms (8% and 0%), gastrointestinal disturbance 
(6% and 0%), and neuropathy (24% and 0%).141
ANG1005, another newer form of paclitaxel, is made up 
of one molecule of angiopep-2 (brain peptide vector) joined 
together with three molecules of paclitaxel. ANG1005 enters 
the brain to a greater extent than paclitaxel and bypasses the 
Pgp efflux pump mechanism.142 This formulation gives new 
hope for treatment of brain metastasis from various forms 
of tumors.
Patient perspectives
Quality of life, although an important consideration, has not 
in the past been the primary endpoint of front-line chemo-
therapy trials, because OS is considered the most important 
issue. It is believed that patients will prefer a therapy which 
prolongs life at the expense of nonthreatening toxicities 
impacting quality of life. However, this notion is not true for 
recurrent ovarian cancer where cure is not yet possible and 
therefore palliation of symptoms and toxicities is of critical 
value. Because the dosing strategy for paclitaxel has a great 
impact on its toxicity profile and hence quality of life, the 
better tolerated weekly low-dose paclitaxel regimens are 
fast emerging as the preferred therapy in recurrent ovarian 
cancer.99,100
Conclusions
In past two decades, taxanes have emerged as front-line che-
motherapy agents in several types of human cancers. Paclitaxel 
for ovarian cancer epitomizes this notion and is the current 
standard front-line therapy along with carboplatin. Having 
already learned about the efficacy of paclitaxel in ovarian 
cancer, future areas of active exploration include finding the 
optimal dosing schedule, investigating newer and potentially 
better forms of paclitaxel, and identifying the optimal route of 
administration.
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